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Background: Proteases that degrade the amyloid ß-protein (Aß) have emerged as key players in the etiology and
potential treatment of Alzheimer’s disease (AD), but it is unlikely that all such proteases have been identified. To
discover new Aß-degrading proteases (AßDPs), we conducted an unbiased, genome-scale, functional cDNA screen
designed to identify proteases capable of lowering net Aß levels produced by cells, which were subsequently
characterized for Aß-degrading activity using an array of downstream assays.
Results: The top hit emerging from the screen was ß-site amyloid precursor protein-cleaving enzyme 2 (BACE2), a
rather unexpected finding given the well-established role of its close homolog, BACE1, in the production of Aß.
BACE2 is known to be capable of lowering Aß levels via non-amyloidogenic processing of APP. However, in vitro,
BACE2 was also found to be a particularly avid AßDP, with a catalytic efficiency exceeding all known AßDPs except
insulin-degrading enzyme (IDE). BACE1 was also found to degrade Aß, albeit ~150-fold less efficiently than BACE2.
Aß is cleaved by BACE2 at three peptide bonds—Phe19-Phe20, Phe20-Ala21, and Leu34-Met35—with the latter
cleavage site being the initial and principal one. BACE2 overexpression in cultured cells was found to lower net Aß
levels to a greater extent than multiple, well-established AßDPs, including neprilysin (NEP) and endothelin-
converting enzyme-1 (ECE1), while showing comparable effectiveness to IDE.
Conclusions: This study identifies a new functional role for BACE2 as a potent AßDP. Based on its high catalytic
efficiency, its ability to degrade Aß intracellularly, and other characteristics, BACE2 represents a particulary strong
therapeutic candidate for the treatment or prevention of AD.
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Alzheimer disease (AD) is a progressive and presently
incurable neurodegenerative disorder characterized by
abnormal accumulation of the amyloid β-protein (Aβ) in
brain regions important for mnemonic and cognitive
functions. Aß is a heterogeneous mixture of peptides
ranging from 37 to 43 amino acids in length [1] pro-
duced via sequential cleavage of the amyloid precursor
protein (APP) by BACE1 and the presenilin/γ-secretase
complex [2-4]. Autosomal-dominant mutations in 3
genes—APP and presenilin-1 and −2—are known to
cause rare, familial forms of AD either by increasing the
production of all forms of Aß or by increasing the rela-
tive production of longer, more amyloidogenic forms,* Correspondence: leissring@mayo.edu
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distribution, and reproduction in any mediumsuch as Aß42 [5]. Nevertheless, the precise mechanisms
underlying sporadic AD, which makes up the vast major-
ity of cases, remain to be elucidated.
Aß-degrading proteases (AßDPs) are potent regulators
of cerebral Aß levels and, as such, represent important
players in the etiology and potential treatment of AD
[6]. Amyloidogenesis and downstream cytopathology can
be attenuated and even completely prevented by enhan-
cing the activity of any of several AßDPs, while, con-
versely, genetic deletion of one or more AßDPs leads to
significant elevations in cerebral Aß [7]. Significantly,
patients with sporadic AD were recently shown to ex-
hibit defects in the clearance of Aß (rather than
increases in its production) [8] and, in light of the large
body of evidence implicating AßDPs in the regulation of
cerebral Aß levels [7], it is reasonable to infer that
defects in one or more AßDPs could contribute totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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teases are now known to degrade Aß [7], these were not
identified through any systematic approach, but instead
emerged haphazardously from a disconnected set of
largely serendipitous discoveries. Nevertheless, essen-
tially all AßDPs now known to regulate Aß in vivo were
originally identified through exclusively in vitro or cell-
based approaches [9].
To discover new AßDPs more systematically, we con-
ducted an unbiased, cell-based, functional screen of 352
proteases in the human genome. The top Aß-lowering
protease emerging from this screen was ß-site APP-
cleaving enzyme-2 (BACE2) [10]. Previous studies have
shown that BACE2 can lower Aß levels via α-secretase-
like cleavage of APP within the Aß sequence [11-16], an
activity that has been dubbed “θ-secretase” [17]. How-
ever, we found that BACE2 is also a remarkably avid
AßDP, with a catalytic efficiency exceeding all other
known AßDPs except insulin-degrading enzyme (IDE).Results and discussion
Functional screen for novel AßDPs
To identify novel AßDPs, we performed a cell-based
functional screen using a commercial library consisting
of 352 full-length, sequence-verified, human cDNAs en-
coding diverse members of all protease classes. We
experimented with several approaches before settling on
a final configuration for the primary screen. Assays
designed to monitor degradation of exogenous Aß were
found to be confounded by the highly dominant effect of
IDE, which mediates the vast majority of extracellular
Aß degradation in cultured cells [18-20]. Transient
transfection of cDNAs into cell lines stably expressing
APP was also tried, but this approach suffered from in-
complete transfection efficiency, which attenuated the
effect on net extracellular Aß levels. We therefore
elected to conduct the screen by co-transfecting prote-
ase-encoding cDNAs, together with positive and nega-
tive controls, into a rodent cell line (CHO cells) together
with a plasmid encoding wild-type human APP fused to
alkaline phosphatase (AP) (see Figure 1A; Methods). Use
of the APP-AP construct ensured that human Aβ pro-
duction was limited to cells also expressing candidate
AßDPs, while also providing an internal control for
transfection efficiency (via AP activity). Importantly, the
co-transfection strategy also increased the likelihood of
detecting AßDPs that degrade Aß intracellularly, prior
to its secretion, in addition to those that act exclusively
extracellularly. Cytotoxicity was also quantified via an
MTT conversion assay, but no significant cell death was
detected so these data were not incorporated into subse-
quent analyses. The screen was performed in quadrupli-
cate and, for each well, the ratio of Aß40 concentrationto AP activity was calculated, then normalized to appro-
priate intra-plate controls (Figure 1B).
From among the 352 proteases examined, by far the
largest decrease in normalized Aß levels (97 ± 1.2%) was
induced by BACE2, which was in fact the only protease
to lower Aß levels more than 75%, our pre-determined
cut-off for viable hits (Figure 1B).BACE2 transfection lowers Aβ levels
To confirm and extend the results obtained in the
cDNA screen, we compared the degree to which overex-
pression of BACE2 and its homolog BACE1 [21] affected
the net production of different Aß species. Consistent
with the results of the primary screen, BACE2 transfec-
tion in CHO cells decreased the levels of both Aβ40 and
Aβ42 (Figure 1C). Overexpression of BACE1 in this cell
type, by contrast, had no effect on net Aß levels
(Figure 1C). We note that BACE1 overexpression would
not be expected to increase Aß production in CHO cells,
since previous studies have established that γ-secretase,
rather than ß-secretase, is the rate-limiting step in Aß
production in this cell type [22].BACE2 and BACE1 degrade Aß in vitro
Expression of BACE2 in cells could lower Aß levels ei-
ther directly, via proteolytic degradation, or indirectly,
via alternative mechanisms such as hydrolysis of APP or
APP C-terminal fragments (CTFs) [11-16]. To distin-
guish these possibilities, we tested the ability of recom-
binant BACE2 to hydrolyze synthetic Aß in vitro, using
a well-established fluorescence polarization-based Aß
degradation assay [23]. Recombinant BACE2 was found
to avidly degrade Aß in this paradigm, confirming that
BACE2 is indeed a bona fide AßDP (Figure 2A). Recom-
binant BACE1 also hydrolyzed Aß, indicating that it too
is an AßDP (Figure 2B). However, BACE1 was much less
efficient than BACE2, requiring 24 h to degrade Aß to a
similar extent as was achieved following a 10-min incu-
bation with BACE2 (Figure 2B). Based on these results,
the efficiency of BACE1 would appear to be ~150-fold
lower than that of BACE2.BACE2-mediated Aß degradation is pH-dependent
As an aspartyl protease, the catalytic efficiency of
BACE2 is expected to be pH-dependent. To confirm
this, we compared the rate of hydrolysis of Aß40 across
a range a pH values. Consistent with expectations,
BACE2 was found to be maximally effective at pH 3.5
(Figure 2C), and decreasingly effective at higher pH
values. These findings strongly suggest that BACE2
would not be operative at the cell surface or within the
extracellular space.
Figure 1 Overview and outcome of functional screening for novel Aß-lowering proteases. A, Cartoon illustrating the overall design of the
screen. Briefly, an arrayed collection of 352 protease-encoding cDNAs was cotransfected into CHO cells together with an APP-AP fusion construct.
Following a medium change and overnight incubation, Aß40 levels, AP activity, and cytotoxicity (via MTT assay) were analyized in the resulting
conditioned media. B, Results of the screen, expressed as [Aß40]/AP ratios normalized to intraplate controls. Data are mean of 4 replicates. Note
that the largest decrease in Aß levels by far was acheived by BACE2. C, Confirmation of the results of the screen. Following scale-up and
sequence verification, cDNAs encoding BACE2 and its homolog, BACE1, were cotransfected together with APP-AP into CHO cells. Consistent with
the outcome of the medium-throughput screen, BACE2, but not BACE1, expression resulted in significant decreases in the levels of both Aß40
and Aß42. Data are mean ± SEM of 4 replicates, and are normalized to vector-only controls.
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Individual AßDPs can be categorized in terms of their
ability or inability to degrade fibrillar forms of Aß. Many
well-established AßDPs, such as IDE and NEP, avidly de-
grade monomeric Aß but cannot degrade fibrillar forms
and are therefore categorized as pure peptidases. Others,
such as plasmin, degrade Aß fibrils and thus can also be
categorized as fibrilases [7]. To determine to which cat-
egory BACE2 belongs, we incubated recombinant
BACE2 with pre-formed fibrils of Aß42 and quantified
the degree of aggregation by thioflavin T fluorescence.
No significant reduction in aggregation was observed,
even following incubation at 37°C for up to 3 d
(Figure 2D). These results suggest that, as is true for the
majority of AßDPs [7], BACE2 does not degrade Aß
fibrils.
BACE2 cleaves Aß at 3 sites
We next investigated which peptide bond(s) within Aβ
are hydrolyzed by BACE2 and BACE1. To that end, we
co-incubated N-terminally biotinylated Aβ40 or Aβ42
(300nM) with BACE2 (5 nM) and analyzed the productsby immunoprecipitation/mass spectrometry (IP/MS)
(see Methods). Within 1 h, BACE2 almost completely
hydrolyzed both Aß species, generating the shorter frag-
ment, Aβ34, in both cases (Figure 3A-D). To test
whether any additional cleavages can occur, we incu-
bated N-terminally biotinylated Aβ40 (300 nM) with a
larger amount of BACE2 (25 nM) for 1 and 24 h. At
these higher concentrations and longer incubation times,
Aβ19 and Aβ20 were the principal N-terminal fragments
remaining at the end of the reaction (Figure 3E-F). Col-
lectively, these in vitro results suggest that BACE2
cleaves Aβ at three different positions: Phe19-Phe20,
Phe20-Ala21, and Leu34-Met35, with the latter cleavage
site being the initial and principal one, as is consistent
with previous observations [13,14,24].
To confirm whether BACE2 cleaves Aβ at the same
sites in a more physiological setting, we analyzed Aß
species in the conditioned media of cells expressing
APP-AP either alone or together with BACE2 by IP/MS
(see Methods). As expected for cells expressing APP-AP
alone, the medium from these cells contained Aβ42,
Aβ40, Aβ39, Aβ38, and Aβ37 (Figure 4A). BACE2
Figure 2 BACE2 degrades Aß in vitro. A, Percent Aß remaining following incubation with different concentrations of recombinant BACE2 for
various lengths of time. Data are mean ± SEM of 4 replicates, normalized to protease-free controls. B, Comparison the relative Aß-degrading
ability of recombinant BACE2 vs. BACE1. Note that 24 h incubation with BACE1 was required to achieve approximately the same extent of
degradation as effected by BACE2 in 10 min. Data are mean ± SEM of 3 replicates, normalized to protease-free controls. C, BACE2 activity is pH
dependent. Percent Aß degradation catalyzed by equivalent amounts of BACE2 at different pH values. Data are mean ± SEM of 4 replicates.
D, BACE2 does not degrade fibrillar Aß. Lack of effect of BACE2 (10 nM) on preformed Aß42 fibrils following incubation at 37°C for 5 d, as
determined by thioflavin T fluorescence. Data are mean ± SEM of 3 replicates.
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and new peaks corresponding to Aβ19, Aβ20, and Aβ34
emerged (Figure 4B), confirming that the cleavage sites
mediated by BACE2 in vitro are also hydrolyzed in intact
cells. The appearance of Aß34 is particularly notable, be-
cause cleavage at position 34 can only occur after pro-
duction of full-length Aß, as this peptide bond is
positioned within the transmembrane domain of APP, as
has been shown previously [24]. Although this result
clearly indicates that BACE2 does indeed degrade Aß
after it is produced, it is not possible to quantify the ex-
tent to which the Aß19 and Aß20 peaks are the result of
θ-secretase activity or subsequent degradation of the
Aß34 fragment (or full-length Aß). As a consequence, it
is difficult to estimate the exact extent to which the Aß-
lowering effect of BACE2 can be assigned to non-
amyloidogenic processing versus Aß degradation per se
in experimental paradigms of this type.
BACE2 degrades Aß more efficiently than well-established
AßDPs
Having established BACE2 as an AßDP, we next investi-
gated how BACE2 compares to other known AßDPs in
terms the ability to degrade Aß in vitro and to lower netAß levels in cells. To compare the relative efficiency of
BACE2 in vitro, we monitored the degradation of a fixed
amount of Aß (200 nM) by recombinant BACE2 (5 nM)
as compared to equal quantities of several well-
established AßDPs, including IDE, NEP and plasmin.
Under these conditions, BACE2 hydrolyzed Aß more ef-
ficiently than all other AßDPs except IDE (Figure 5A).
We note that the concentration of Aß used in this ex-
periment was considerably lower than the KM for each
of the proteases tested (see [23] and below), making the
initial velocity of this reaction a good index of the rela-
tive catalytic efficiency.
Kinetics of Aß degradation by BACE2
To investigate the catalytic efficiency of BACE2 more
quantititatively, we determined the kinetics of degrad-
ation of both Aß40 and Aß42 by BACE2 (see Methods).
For this analysis, we were careful to use freshly prepared
batches of monomeric human Aβ40 and Aβ42 peptides,
which we routinely prepare by size-exclusion chroma-
tography and which have been extensively characterized
[25,26]. BACE2 cleaved both Aß species with similar
kinetics, exhibiting apparent KM values in the low micro-
molar range and albeit with apparent kcat values slightly
Figure 3 Determination of peptide bonds within Aß hydrolyzed by BACE2. Top, Summary of cleavage sites determined from data in A-F,
showing the major site (block arrow) and two minor sites (arrow heads). At t = 0 (A, C), intact Aß42 (A) and Aß40 (C) represent the only species
present. Following incubation of Aß42 and Aß40 with 5nM BACE2 for 1 h (B,D, respectively), the full-length Aß species are essentially completely
absent and replaced by Aß34. E,F, Additional Aß cleavage products are produced following incubation with larger amounts of BACE2 (25 nM) for
longer lengths of time. By 1 h (E), a new peak corresponding to Aß20 is produced. By 24 h (F), Aß20 becomes the major species present, and
Aß19 is also produced. Double-charged fragments are denoted by “+”, and “*” represents the modification of a fragment by AEBSF, which leads
to a 183-Da increase in MW, as previously reported [46].
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and 0.025 ± 0.005 min-1, respectively; Table 1). In terms
of catalytic efficiency (kcat/KM), BACE2 degrades Aβ40
approximately 4-fold more efficiently than Aβ42
(Table 1). These parameters exceed the published values
for most other well-characterized AßDPs, including NEP
[23], ECE1 [27], and plasmin [23], while being compar-
able to those of IDE [23,28]. Consequently, these values
are in good agreement with the side-by-side comparison
of Aß degradation in vitro discussed above (Figure 5A).
To investigate the relative ability of BACE2 to lower
Aß levels under more physiological conditions, we co-
transfected CHO cells with APP together with BACE2
or several other AßDPs, then quantified net Aß40 and
Aß42 levels in the conditioned medium by ELISA. We
emphasize that this approach cannot control for intrinsic
differences in transcription or translation efficiency, and,in the case of BACE 2, the Aß-lowering effect can also be
mediated to an undetermined degree by BACE2-mediated
θ-secretase activity. Nevertheless, the results were in good
agreement with the in vitro findings: BACE2 lowered net
Aß40 and Aß42 levels to a comparable extent as IDE,
with both of the latter being significantly more effective
than NEP or plasmin (Figure 5B, C).
BACE2 colocalizes with Aβ intracellularly
Having determined that BACE2 is functionally among
the most efficient AßDPs yet discovered, we subse-
quently investigated the subcellular localization of
BACE2, focusing in particular on the extent to which it
colocalizes with Aβ in acidic compartments, where
BACE2 is expected to be operative. In agreement with
other published findings [29], application of fluores-
cently tagged Aß to live cells resulted in its
Figure 4 Overexpression of BACE2 in cells yields Aß fragments identical to those produced in vitro. A,B, Spectra of Aß fragments
determined by IP/MS analysis of the conditioned media of CHO cells transfected with APP and empty vector (A) or APP and BACE2 (B) (see
Methods). A, APP expression alone produces peaks corresponding to Aß42, Aß40, Aß39, Aß38 and Aß37. B, Co-expression of APP and BACE2
results in decreases in the relative abundance of the aforementioned Aß species and the appearance of three new fragments: Aß34, Aß20 and
Aß19. Double-charged fragments are denoted by “+”, and “*” represents the modification of a fragment by AEBSF, which leads to a 183-Da
increase in MW, as previously reported [46].
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with lysosomes (Figure 6A). To test whether BACE2 is
also localized to lysosomes and/or other compartments
containing Aß, we analyzed CHO cells expressing
BACE2 tagged at its N-terminus with green fluorescent
protein (BACE2-GFP). As determined by confocal mi-
croscopy, BACE2-GFP was found to be present in lyso-
somes (Figure 6B) and also to overlap significantly with
fluorescently labeled Aß (Figure 6C).
BACE2 degrades Aß at intracellular sites
To directly assess whether BACE2 degrades Aß at intra-
cellular sites, we tested the ability of BACE2-expressing
cells to degrade exogenously applied Aß by multiple
methods. Cells overexpressing BACE2-GFP and loaded
with fluorescently tagged Aß40 showed significantly
reduced intracellular Aß 1 h after washing, but this was
not the case for cells overexpressing GFP alone
(Figure 7A). Consistent with this, levels of intracellular
Aß, both fluorescently tagged and unmodified, were
found to be consistently lower in cells overexpressing
(untagged) BACE2 relative to vector-trasfected controls
(Figure 7B,C). Notably, significantly lower levels of intra-
cellular Aß were observed both 5 min and 2 h after
washing in multiple paradigms. Collectively, these results
strongly suggest that BACE2 is a bona fide AßDP that
avidly degrades Aß within acidic compartments.
Conclusions
One of the most fruitful outcomes of the genomic revo-
lution is the emergence of genome-scale collections of
full-length, sequence verified cDNAs. Combined withappropriate functional assays, cDNA libraries have cat-
alyzed significant advances in our understanding of
AD pathogenesis, including the seminal discovery that
ß-secretase activity, the first step in the production of
Aß, is mediated by BACE1 [21]. Here, we utilized a similar
approach to discover new candidate AßDPs, using a func-
tional assay sensitive to both extracellular and intracellular
Aß degradation (as well as other potential Aß-lowering
mechanisms). Rather unexpectedly, the top hit emerging
from a screen of 352 proteases was BACE2, a close homo-
log of BACE1. Subsequent characterization confirmed
that, in addition to BACE2’s established ability to lower
Aß production via θ-secretase-mediated processing of
APP [11-16], BACE2 also avidly degrades Aß with a cata-
lytic efficiency exceeding almost all well-established
AßDPs.
The finding that BACE2 is an avid AßDP suggests a
novel and unexpected role for this protease in the
pathogenesis of AD. Indeed, given its close homology
with BACE1, it was initially hypothesized that BACE2
might mediate the production of Aß, via β-secretase
cleavage of APP, instead [15,16]. However, most evi-
dence now suggests that BACE2 does not contribute
appreciably to Aß production in vivo [3]. For instance,
cultured neurons from BACE2 knockout mice did not
show reductions in Aß following transfection with APP
[30] and conversely, overexpression of BACE2 in APP
transgenic mice failed to increase cerebral Aß levels, as
would be expected if BACE2 possessed ß-secretase-like
activity.
In addition to its potent ability to degrade Aß, BACE2
also possesses a second Aß-lowering function for
Figure 5 Comparison of the efficacy of BACE2 relative to other well-established AßDPs in vitro and in cultured cells. A, Degradation of
Aß in vitro by equivalent nominal concentrations (5 nM) of recombinant BACE2, IDE, NEP and plasmin. Note that BACE2 degrades Aß at a faster
rate than NEP and plasmin, but not IDE. B,C, Effects on Aß40 (A) and Aß42 (C) levels following cotransfection of CHO cells with APP together with
equivalent quantities of cDNAs encoding BACE2, ECE1b and IDE. In good agreement with the results in vitro (A), BACE2 lowers the levels of both
Aß species to an extent exceeding NEP and ECE1b, but comparable to IDE. Data are mean± SEM of 4 replications, normalized to controls
cotransfected with empty vector (Vo).
Abdul-Hay et al. Molecular Neurodegeneration 2012, 7:46 Page 7 of 12
http://www.molecularneurodegeneration.com/content/7/1/46BACE2, one that is quite independent of Aß degradation.
Specifically, BACE2 has been shown to cleave APP and
the ß-secretase-derived APP-CTF within the Aß se-
quence, in a manner analogous to α-secretase [11-16].
This activity, dubbed θ-secretase [17], occurs at positions
19 and 20 within the Aß sequence, precisely the same
cleavage sites identified in the present study [13,14]. As is
true for α-secretase, θ-secretase activity lowers Aß levels
by shuttling APP away from the amyloidogenic proces-
sing pathway [11-16].Table 1 Kinetic parameters of Aß40 and Aß42
degradation by BACE2
Aß40 Aß42
KM (μM) 2.8 ± 0.7 2.3 ± 0.6
Vmax (μM min
-1) 0.68 ± .083 0.12 ± 0.025
kcat (min
-1) 0.135± 0.016 0.025 ± 0.005
kcat/KM (M
-1min-1) 4.82 x 107 1.07 x 107As confirmed by previous work [24], we found that
BACE2 also cleaves Aß at the Leu34-Met35 peptide
bond, which was in fact the initial and principal site of
cleavage. Notably, cleavage at this position can only
occur after production of full length Aß by ß- and
γ-secretase, because this peptide bond in APP or in APP
CTFs is normally embedded within the cell membrane
[24]. This fact, together with the finding that Aß34 is pro-
duced in cells overexpressing of BACE2 and APP, provides
clear evidence that the Aß-degrading activity of BACE2
contributes significantly to the overall Aß-lowering effect
of BACE2 overexpression, even in the context of concur-
rent θ-secretase activity.
Given that BACE2 can lower Aß both by decreasing
its production and by mediating its degradation, which
of these mechanisms are relevant to the pathogenesis or
the potential treatment of AD? The answer depends crit-
ically on precisely where and to what extent BACE2 is
expressed in vivo. Although BACE2 protein is readily
Figure 6 BACE2 is localized to intracellular compartments relevant to Aß degradation. A, Exogenous administration of fluorescently
labeled Aß40 (green) to CHO cells results in accumulation at intracellular sites overlapping with lysosomes, as labelled by Lysotracker Red (red)
and visualized by confocal microscopy. B, BACE2 is expressed in multiple intracellular compartments, including lysosomes. Distribution of GFP-
tagged BACE2 (green) in cells labeled with Lysotracker Red (red) shows significant localization within lysosomes (yellow). C, BACE2 colocalizes with
exogenously administered Aß. Confocal images showing significant overlap (yellow) between BACE2 (green) and fluorescently labeled Aß (red). For
these experiments, cells were imaged within 5 minutes of washing in cold PBS to remove medium containing excess fluorescently labeled Aß.
Note that the the majority of BACE2-GFP-expressing cells contianed very low levels of fluorescent Aß (see Figure 7), and the particular cell shown
exhibited relatively high levels of internalized Aß, allowing us to highlight the overlap with BACE2.
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even been shown to be comparable to that of BACE1 in
post-mortem brain [31,33], there is conflicting evidence
about which cell types express BACE2. Studies in mice,
on the one hand, suggest that the protease is expressed
abundantly in glia but only minimally in neurons [30].
To the extent that these findings apply to humans,
θ-secretase cleavage of APP by BACE2 would be un-
likely to play any significant pathophysiological role in
AD, given that APP itself is expressed predominantly in
neurons, with only modest expression levels in non-
neuronal brain cells [31]. On the other hand, multiple
studies in post-mortem human brain tissue have
reported detectable BACE2 expression not only in
astrocytes, but also in neurons [15,33], suggesting that
the θ-secretase activity of BACE2 may, to some extent,
contribute to the overall economy of brain Aß. Thepathophysiological relevance of BACE2’s function as
an AßDP is similarly difficult to predict and likewise
dependent on the extent to which the protease is
expressed in neurons. Astrocytes are known mediate
the clearance of Aß [37], but the contribution of
intra-astrocytic Aß degradation relative to intraneuro-
nal or extracellular degradation in vivo remains to be
established. As was true for other AßDPs first identi-
fied in cells [9], the answer to these questions will re-
quire further study in relevant animal models.
Notwithstanding uncertainty about its role in AD
pathogenesis, a number of considerations suggest that
BACE2 represents an especially strong therapeutic can-
didate, particularly for gene therapy-based approaches.
BACE2 can lower Aß catalytically via two independent
mechanisms, and its Aß-degrading ability alone exceeds
that of most other AßDPs, some of which are being
Figure 7 BACE2 degrades Aß at intracellular sites. A, CHO cells expressing GFP-BACE2 (green, left), but not those expressing GFP alone (green,
right), exhibit marked reductions in intracellular Aß (red). For these experiments, cells were loaded for 6 h with 400 nM fluorescently labeled Aß40,
washed, then incubated at 37°C for 1 h prior to imaging by conventional fluorescence microscopy. B,C, BACE2 overexpression significantly lowers
intracellular Aß. B, Quantification of intracellular pools of fluorescently labeled Aß40 in CHO cells 0 and 2 hours after loading. C, Relative levels of
intracellular (unmodified) Aß40 in CHO cells 0 and 2 hours after loading, as quantified by ELISA. Data are mean ± SEM of 3 replicates, normalized
to vector-only controls. *P <0.05 by Tukey’s multiple comparisons test.
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over, as an aspartyl protease, BACE2 possesses distinct
advantages relative to other AßDPs. First, it is operative
with subcellular compartments most relevant to Aß pro-
duction—i.e., those containing active ß- and γ-secretase,
which are both aspartyl proteases—thus allowing it to
impact Aß levels prior to secretion. In this connection,
there is growing evidence that intracellular Aß may rep-
resent an especially pathogenic role in AD [39], so
modulation of this pool may be particularly appropriate
therapeutically. Second, because BACE2 is operative ex-
clusively at intracellular sites, its expression could be
readily restricted to the site of administration. This is incontrast to many other AßDPs which are secreted and/
or active extracellularly [19,40,41] and thus less capable
of being confined to specific regions.
In conclusion, this study identifies BACE2 as a novel
and highly efficient AßDP. This newly identified func-
tion of BACE2, together with its established ability to
also lower Aß production via θ-secretase activity, sug-
gests that BACE2 may play a significant role in AD
pathogenesis. Moreover, even if BACE2 plays no role in
the etiology of AD, BACE2 nevertheless represents a
particularly attractive candidate for gene therapeutic
approaches to the treatment of prevention of this pres-
ently incurable disease.
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cDNA screening
A library of 352 full-length, sequence verified, human
cDNAs encoding diverse members of all protease classes
was purchase from a commercial source (OriGene Tech-
nologies, Inc.) in 96-well format (100 ng/well). For nega-
tive and positive controls, a subset of blank wells on
each plate were supplemented with empty vector or a
construct expressing a well-established AßDP, human
ECE1b [27], respectively (100 ng/well). As a source of
human Aß and also as a transfection control, each well
was cotransfected with a hybrid construct, APP-AP
(60 ng/well), comprised of a vector expressing wild-type
human APP fused at its N-terminus with alkaline phos-
phatase (AP) [42]. Additional blank wells were left un-
treated for cell-free background controls. CHO cells
(4.8 x 104/well) suspended in DMEM/Opti-MEM sup-
plemented with 5%FBS were then co-transfected with
APP-AP and protease-encoding cDNAs using Fugene
6.0, according to manufacturer’s recommendations
(Promega Corp.). Transfected cells were allowed to
grow overnight under standard cell culture conditions
(5% CO2; 37°C; 95% humidity) then the medium was
exchanged. 24 h later, the conditioned media were col-
lected for downstream analysis (see below). All experi-
ments were conducted in compliance with and with
approval by the Mayo Clinic Institutional Review Board.AP activity
Following heat treatment to inactivate endogenous phos-
phatases (65°C for 15 min) present in the media, condi-
tioned media (30 μL/well) was added to 96-well plates
containing AP substrate, 4-nitrophenylphosphate (170 μL/
well, 2 mg/mL), dissolved in AP buffer (1 M diethanola-
mine, 0.5 mM MgCl2, 10 mM L-homoarginine, pH 9.8).
Plates were incubated for 30 min and AP activity was
determined from absorbance (OD405) using a Spectra-
MaxW M5e multilabel plate reader (Molecular Devices).Aβ ELISA
Aβ levels were quantified using a sandwich ELISA sys-
tem based on antibody pairs 33.1.1/13.1.1 for Aβ40 and
2.1.3/4 G8 for Aβ42 as described previously [43]. Condi-
tioned media were supplemented with CompleteTM Pro-
tease Inhibitor Cocktail (Roche) just after collection and
analyzed immediately. For experiments quantifying
intracellular Aß, cells were plated in in 96-well plates
(2 x 104 cells per well) and transfected with BACE2-
encoding cDNA or empty vector, washed, then incubated
with 400 nM synthetic Aß for 6 h. After washing with
PBS, intracellular Aß was extracted with 5 M guanidi-
nium isothiocyanate and quantified using a commer-
cially available ELISA (Wako Chemicals USA, Inc.)after 10-fold dilution in the manufacturer-provided di-
lution buffer.
Mass spectrometry
The cleavage sites within Aβ40 and Aβ42 hydrolyzed by
BACE2 and BACE1 were determined essentially as
described [44] with minor modifications. Briefly, Aβ
peptides or biotinylated Aβ peptides were incubated for
various lengths of time with recombinant BACE2 en-
zyme in Assay Buffer (25 mM acetate buffer, pH 4.0,
supplemented with 0.1% BSA). The reaction was stopped
by addition of protease inhibitor cocktail and pH adjust-
ment. Aβ fragments were immediately precipitated by
magnetic beads coated with streptavidin (for biotinylated
Aβ) or magnetic beads coated with Ab9 antibody [45]
(for unmodified Aβ). Beads were washed with 10 mM
NH4CO3, pH 8.0, and peptide fragments were eluted
using 0.5% trifluoroacetic acid in 75% acetonitrile in
water, followed by the addition of an equal volume of a
saturated sinapic acid solution dissolved in 0.5% trifluor-
oacetic acid in 50% acetonitrile and water. Digested pro-
ducts were spotted onto a gold chip, dried, and analyzed
using a Ciphergen ProteinChip SELDI time-of-flight sys-
tem (Bio-Rad). Mass spectra were acquired automatically
in a linear positive mode at 1350 shots per spectrum.
Peptides containing a183-Da increase in MW were iden-
tified as being modified by AEBSF, as previously
reported [46]. Same procedure was applied to detect the
endogenous Aβ fragments produced by CHO cells trans-
fected with APP and BACE2 (using Ab9 as a capture
antibody).
In vitro analyses of Aβ degradation by BACE2
The kinetics of Aβ40 and Aβ42 degradation by
BACE2 were determined using freshly prepared,
monomeric Aβ peptides separated from aggregated
species by size-exclusion chromatography and charac-
terized as described [25,26]. Aβ peptides were diluted
in neutral Dilution Buffer (20 mM Tris, pH 8.0 supple-
mented with 0.1% BSA) and reactions were initiated by
transfer into 20 times more volume of Assay Buffer sup-
plemented with purified recombinant BACE2 (R&D Sys-
tems, nominal concentration 1 or 5 nM) or, as a control
for non-specific loss of Aβ, the latter buffer lacking
BACE2. Where required, reactions were terminated
by supplementation with protease inhibitor cocktail
and adjustment to neutral pH. For ELISA-based
experiments, Aβ42 and Aβ40 were quantified using
the sandwich ELISAs described above. For determin-
ation of kinetic parameters, ELISAs were used to quan-
tify the initial velocities of degradation of a range of
different concentrations of Aß40 (0.2 to 16 μM) or
Aß42 (0.6 to 16 μM) by a fixed amount of recombinant
BACE2 (5 nM) in Assay Buffer, and KM and vmax values
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curve to these data in Prism 5.0 (GraphPad Software,
Inc.). For determination of the pH dependence of Aβ
degradation, experiments were carried same as
described above, using Assay Buffer at different pH
values (3.0, 3.5, 4.0, 4.5, 5.0, 5.5). The reactions were
stopped at 10 min and the remaining 200nM of Aβ was
determined using a well-characterized fluorescence
polarization-based activity Aß degradation assay, as
described [23]. For comparison of the rate of degrad-
ation of Aβ by different proteases, we incubated 200 nM
of Aβ fluorescent substrate (FAβB) with 5nM of differ-
ent protease in their corresponding buffers: BACE1 and
BACE2 using Assay Buffer and IDE, NEP, and plasmin
in PBS, pH 7.4 supplemented with 0.1% BSA. The reac-
tions were stopped by addition of protease inhibitor
cocktail, 500nM streptavidin, and adjustment to neutral
pH. The degree of Aβ hydrolysis was immediately deter-
mined using a polarization-based Aß degradation assay
[23]. Recombinant BACE2 (R&D Systems) and plasmin
(EMD Biosciences) were purchased from commercial
sources, while recombinant IDE and secreted NEP (i.e.,
lacking the transmembrane domain) were generated
and purified as described [23]. All reactions were per-
formed at 37°C.
Fluorescence microscopy
CHO cells (106 cells/cm2) were plated onto 8-well poly-
D-lysine-coated, glass-bottom chambers (MatTek Corp.)
in culture medium (DMEM/Opti-MEM supplemented
with 5%FBS). For BACE2 transfections, cell were trans-
fected with a construct encoding BACE2 tagged at its
C-terminus with GFP (OriGene Technologies, Inc. Cat.
No. RG04860) using Fugene 6.0 transfection reagent
according to manufacturer’s recommendations (Pro-
mega Corp.). For Aβ colocalization experiments, cells
were washed twice in fresh culture medium, then incu-
bated in the latter medium supplemented with either
Aß40 (500 nM) labeled at the N-terminus with HiLight
FluorTM 488 or HiLight FluorTM 555 (AnaSpec, Inc.). For
lysosomal staining, cells were incubated with Lysotracker
Red according to manufacturer’s recommendations (Invi-
trogen Corp.), then washed 2 times with fresh culture
medium prior to imaging. For confocal microscopy, cells
were washed with fresh medium then imaged immedi-
ately using the 488-nm and 543-nm laser lines on a Zeiss
LCM 510 META confocal microscope (Carl Zeiss, Inc.).
Images were processed and analyzed using MetaMorph
software according to manufacturer’s recommendations
(Molecular Devices, Inc.). For conventional fluorescence
microscopy of intracellular Aß, cells were washed with
fresh medium, then incubated at 37°C for 1 h prior to
imaging using a Nikon Labophot 2 fluorescent micro-
scope (Nikon Inc.).Abbreviations
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